Bipartisan Insulin Bill Could Cap Costs at $35 Monthly

After years of Americans rationing a century-old medication, lawmakers from both parties just introduced a bill that could make insulin affordable for nearly everyone.

The INSULIN Act of 2026 would cap out-of-pocket costs at $35 per month for people with private insurance. It also creates a $100 million pilot program to help uninsured Americans access the same low price.

Senators Raphael Warnock, Jeanne Shaheen, John Kennedy, and Susan Collins are leading the effort. Their coalition spans both Democrats and Republicans, a rare sight in today's divided Washington.

The bill builds on protections already in place for Medicare patients, who got their $35 cap through the Inflation Reduction Act. Now the lawmakers want to extend that relief to the roughly 8 million Americans who use insulin but aren't on Medicare.

Insulin has become the poster child for high drug prices in America. Its core ingredient was discovered about 100 years ago, yet prices have skyrocketed in recent years despite minimal changes to the formula.

The new legislation goes beyond just price caps. It creates new requirements for pharmacy benefit managers, the middlemen who negotiate drug prices and often add hidden costs. It also aims to increase competition by making it easier for biosimilar and generic versions to reach the market.

The Ripple Effect

Timing matters here. The Federal Trade Commission just reached settlements with major pharmacy benefit managers over allegations they artificially inflated insulin prices. CVS Caremark agreed to a proposed settlement last week, following a similar deal with Cigna's Express Scripts in February.

These enforcement actions, combined with bipartisan legislative momentum, suggest real change could be coming. When regulators crack down and lawmakers work together, patients win.

The bill also comes as broader healthcare reforms are being debated in Congress. Some Republicans are considering using special budget procedures to pass other healthcare changes, which could create more opportunities for patient-focused legislation.

While a similar bill didn't pass in 2023, the political landscape has shifted. Public outrage over drug prices has only grown, and the Medicare cap has proven the concept works without disrupting the insulin market.

For millions of Americans who depend on insulin to survive, affordable access isn't a political issue. It's about whether they can afford both their medication and their rent, both their prescriptions and their groceries.

This bipartisan effort shows that when the stakes are high enough, lawmakers can still find common ground.

##